| Filed On | Filing |
|---|---|
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
Portfolio Receipts growth of 9% to $890 million; Royalty Receipts growth of 9% |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
Portfolio Receipts growth of 6% to $773 million; Royalty Receipts growth of 14% |
| 04 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 4, 2026, Royalty Pharma plc (the “Company”) held its 2026 Annual General Meeting of Shareholders (the “Annual Meeting”). At the Annual Meeting, the Company’s shareholders voted on 10 proposals, each of which is described in more ... |
| 28 May 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
and the Lenders and the Issuing Banks from time to time party hereto |
| 06 May 2026 |
8-K: Results of Operations and Financial Condition
Portfolio Receipts growth of 10% to $925 million; Royalty Receipts growth of 13% |
| 13 Apr 2026 |
8-K: Regulation FD Disclosure
On April 13, 2026, Revolution Medicines, Inc. (“Revolution Medicines”) announced positive Phase 3 results from the RASolute 302 trial for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, in patients with metastatic pancreatic duc... |
| 11 Feb 2026 |
8-K: Results of Operations and Financial Condition
NEW YORK, NY, February 11, 2026 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth |
| 22 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 22 Dec 2025 |
8-K: Regulation FD Disclosure
On December 19, 2025, Cytokinetics, Incorporated (“Cytokinetics”) announced that the U.S. Food and Drug Administration approved a New Drug Application for MYQORZO (aficamten). MYQORZO is a cardiac myosin inhibitor for the treatment of ad... |
| 05 Nov 2025 |
8-K: Results of Operations and Financial Condition
NEW YORK, NY, November 5, 2025 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third |
| 16 Sep 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
Royalty Pharma plc, a public limited company incorporated under the laws of England and Wales (the “Company”), Royalty Pharma Holdings Ltd, a private limited company incorporated under the laws of England and Wales (“RP Holdings”) and Ro... |
| 13 Aug 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
NEW YORK, NY, August 13, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced that Henry Fernandez, its Lead Independent Director, has stepped down from its Board of Directors, effective August 13, 2025. Mr. Fernandez joined the Roya... |
| 06 Aug 2025 |
8-K: Results of Operations and Financial Condition
Portfolio Receipts growth of 20% to $727 million; Royalty Receipts growth of 11% |
| 17 Jul 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Strengthens Board of Directors with appointment of two new independent members, increasing independent representation to greater than 90% |
| 19 May 2025 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +3 more
1 This document comprises the Articles of Association of Royalty Pharma plc (the “Company”) and no regulations set out in any statute or statutory instrument concerning companies (including the Companies (Model Articles) Regulation 2008 ... |
| 12 May 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On May 12, 2025, Royalty Pharma plc (the “Company”) held its 2025 Annual General Meeting and Special Meeting of Shareholders (the “Annual Meeting”). At the Annual Meeting, the Company’s shareholders voted on 15 proposals, each of which i... |
| 08 May 2025 |
8-K: Results of Operations and Financial Condition
NEW YORK, NY, May 8th, 2025 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts. |
| 11 Apr 2025 |
8-K: Entry into a Material Definitive Agreement
This AMENDMENT NO. 1 TO MEMBERSHIP INTERESTS PURCHASE AGREEMENT (this “Amendment”), is made and entered into as of April 11, 2025, by and among Royalty Pharma Holdings Ltd., a limited company formed under the Laws of England and Wales (“... |
| 10 Apr 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
NEW YORK, NY, April 8, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Vlad Coric, M.D. to the company’s Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer of Bio... |
| 11 Feb 2025 |
8-K: Results of Operations and Financial Condition
NEW YORK, NY, February 11, 2025 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter and full year 2024 and introduced full year 2025 guidance for Portfolio Receipts. |
Loading...